WindMIL
is a biotechnological company that researches and develops bone marrow-derived lymphocytes for cancer immunotherapy... Read moreWindMIL
is a biotechnological company that researches and develops bone marrow-derived lymphocytes for cancer immunotherapy... Read more
Chairman & CEO
Donald J. Hayden
News
Jan 07, 2020
GlobalNewswire
Press Release: WindMIL : WindMIL Therapeutics Expands Leadership Team
Dec 23, 2019
BioSpace
WindMIL: WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs ) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer
Jul 09, 2019
GlobalNewswire
Press Release: WindMIL : WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs )
Jun 25, 2019
GlobalNewswire
Press Release: WindMIL : WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs ) in Non-Small Cell Lung Cancer
Apr 25, 2019
The Business Journals: Baltimore
WindMIL: Former Bristol-Myers Squibb executive named CEO of immunotherapy company
Apr 25, 2019
Talent4Boards
WindMIL: WindMIL Therapeutics appoints its Chairman, Don Hayden, to the additional role of CEO
Apr 17, 2019
FirstWord Pharma
WindMIL: WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth
Mar 25, 2019
Contract Pharma
WindMIL Therapeutics: WindMIL Therapeutics Announces Key Appointment
Feb 01, 2019
BioPharm
WindMIL Therapeutics: TrakCel, WindMIL Therapeutics Partner to Develop Supply Chain Platform
Dec 21, 2018
The Business Journals: Baltimore
WindMIL Therapeutics: Baltimore immunotherapy company opens Philadelphia office
WindMIL Competitors
1
2
3
4
5
6
7
8
9
10